What is the difference between gaviscon and zantac

The placebo was composed of hydrogenated glucose syrup, xanthane gum, methyl parahydroxybenzoate E , propyl parahydroxybenzoate E , erythrosine E , fennel flavour, titanium oxide, and purified water. This outcome was assessed by the GP, based on the self-administered questionnaire filled in 4 times a day by the patient.

Mean time to onset was calculated as the difference between 2 time-points: the time of taking the treatment for the first time and the date and time morning, midday, evening, before bedtime at which a h heartburn-free period had been achieved. Secondary outcomes were: a the mean number of days without heartburn by D7 as assessed from the patient's self-administered questionnaire; b patient's overall qualitative self-assessment of pain relief on D7 on a 5-point Likert scale; and c pain intensity on D7 and D14, assessed by the patient on a mm visual analog scale VAS.

Adverse events AEs were collected at the two study visits D7 and D An AE was defined as an untoward medical event that occurred during the study period, whether or not related to the study procedure or study products. Severe AE SAE was defined as an untoward medical event that resulted in death, was life-threatening, required inpatient admission or prolongation of hospitalization, or resulted in severe or persistent disability or incapacity.

Descriptive statistical analyses were performed on the data collected on D0, D7 and D14, and those of the self-administered questionnaire D0 to D7, and D7 to D14 , for the intention-to-treat ITT and per protocol PP populations. The PP population included all patients from the ITT population who attended at least one of the study visits, except those with major protocol deviations liable to interfere with the primary outcome result.

Inter-group comparability was checked at inclusion for heartburn frequency and severity, GERD duration, age, regurgitation and alcohol consumption. In case of non-comparability, analysis of covariance ANCOVA was performed, introducing into the model the variable or variables that were non-comparable at baseline. Statistical analysis was carried out on SAS version 8. Previous studies showed that the time to a h heartburn-free period was days with placebo [ 13 ], days with rabeprazole 20 mg [ 13 ], and 2 days with pantoprazole 20 mg or omeprazole 20 mg [ 14 ] at least 16 days' difference between placebo and PPI.

Halving this difference gives a non-inferiority limit of 8 days, which was neither ethically nor clinically acceptable. The most recent study [ 14 ] reported a value of 1. If the lower limit 0. In all, patients were required in order to meet the primary endpoint. At inclusion, PP population characteristics were comparable between groups Table 1 and did not differ from those of the ITT population data not shown.

The mean age of included patients PP population was Mean body mass index BMI was Patients had suffered from GERD for a mean 6. Before inclusion, 78 patients No patients reported history of severe esophagitis.

Alcohol consumption and smoking were moderate and comparable between groups. Mean time to onset of the first h heartburn-free period after initial dosing was 2. Mean intergroup difference was 0. Results are therefore presented for the ITT population. Seventeen The percentage of patients with at least one AE was also comparable, regardless of time period: 9. The most frequently observed AEs were nausea 1. All other AEs had an incidence of 0. The GOOD trial is the first randomised controlled double-blind, double-dummy trial to directly compare efficacy between an alginate and a PPI with heartburn as the clinical primary endpoint.

In both groups, 9 out of 10 patients had a heartburn-free period of at least 24 h. The weekly absolute difference was 0. This trial, performed in a general practice setting, included patients with symptoms highly suggestive of GERD heartburn, regurgitation and with a very low estimated risk of ulcerative esophagitis. The same primary outcome was used in a trial comparing rabeprazole vs.

Alginates showed proven efficacy against GERD symptoms in randomised trials vs. The limitation of the GOOD trial was the treatment period, which was only 14 days, with the primary outcome set during the first 7 days of treatment.

As the primary outcome was the time to onset of the first h heartburn-free period, each day was divided into four periods so as to have four symptom assessments per day. As the treatment was symptomatic, this endpoint was relevant clinically and from the patient's point of view. The comparison was between two drugs with different pharmacokinetic and pharmacodynamic properties.

Alginates display immediate action, forming a raft floating over the stomach contents, eliminating or displacing the postprandial "acid pocket", so that, in case of reflux, the raft is regurgitated first into the lower oesophagus, reducing acid contact, especially when the subject is standing [ 16 — 21 ]. The raft may remain in the stomach for several hours [ 18 ] but is then evacuated, so that 3 or 4 doses per day are required for optimal efficacy.

The trial used a simple, relevant and pragmatic primary clinical endpoint rather than a composite score such as symptom frequency plus intensity. In these patients, alginates and antacids were often restricted to self-medication. This is a relevant and useful alternative and an effective non-systemic approach that should help reduce excessive use of curative or preventive prescriptions of PPIs [ 30 ].

PPIs are a well-tolerated pharmacologic class, but concomitant prescription of omeprazole with clopidogrel should be managed carefully after coronary stenting [ 31 — 33 ]. Some authors suggested that prolonged PPI therapy could increase Clostridium difficile infection [ 34 ], community-acquired pneumopathy [ 35 ] and risk of hip fracture [ 36 , 37 ], so that this pharmacologic class should be prescribed in moderation if other safe rapid-relief solutions are available. Spechler SJ: Epidemiology and natural history of gastro-oesophageal reflux disease.

PubMed Google Scholar. Presse Med. Article PubMed Google Scholar. Cochrane Database of Systematic Reviews. DOI: This is why you should wait at least one hour after eating before taking it.

Bedtime is another perfect time to take an antacid, since it will have the chance to provide substantive relief. Ask your pharmacist if you have questions about antacids or over the counter medications.

This information does not constitute medical consultation, diagnosis or opinion and should not be interpreted as such. Please consult your health care provider if you have any questions about your health, medications or treatment.

Ask us a question about the topic of your choice and we'll try to address it in a future article. Home Health Which antacid should you choose? Which antacid should you choose? What are antacids? Which antacid should you choose for rapid relief of acid reflux or sour stomach? Alginate Antacids that contain alginate are very effective at easing acid reflux. Stomach acid neutralizers These antacids relieve both acid reflux and sour stomach by temporarily neutralizing the gastric acid already produced in the stomach.

Antacids that contain both aluminum and magnesium Antacids that contain both aluminum and magnesium e. Which antacid should you choose for long-term relief of acid reflux or sour stomach? Some products provide long-lasting relief, but not immediately. H2 antagonists H2 antagonists, such as ranitidine Zantac and famotidine Pepcid act directly on the cells of the stomach to reduce the quantity of acid produced and are effective for both sour stomach and acid reflux.

Choose a product that contains: 75 mg of ranitidine for 4 to 13 hours of relief 10 mg of famotidine for 10 to 12 hours of relief Proton-pump inhibitors PPI Proton-pump inhibitors such as omeprazole and esomeprazole work by decreasing the amount of acid produced by the stomach for a long-lasting relief of heartburn. Ranitidine is not currently available in the UK or globally. It has been discontinued as a precaution because it may contain a small amount of an impurity that has been linked to an increased risk of cancer in animals.

It's not yet known whether it will be available again in future. Ranitidine is a medicine that reduces the amount of acid your stomach makes.